Drug Trial Radar · NCT04776252
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,000
Planned (sponsor's estimate)
Start
Sep 15, 2021
Primary completion
May 29, 2029
Study completion May 29, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Mar 1, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The safety and tolerability of MK-8591A, a 2-drug fixed dose combination (FDC) of doravirine (100mg) and islatravir (0.75mg) \[DOR/ISL 100 mg/0.75 mg) will be evaluated in participants with Human Immunodeficiency Virus -1 (HIV-1) who were treated with DOR and ISL in earlier clinical studies.
Conditions
- HIV-1 Infection
Interventions
MK-8591ADrug
FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Participants with serious adverse events (SAEs)Time frame: Up to Week 198
- Participants who discontinued due to an adverse event (AE)Time frame: Up to Week 192
Locations
93 sites in 16 countries. Site status is shown where the registry gives one.
Pueblo Family Physicians ( Site 0010)
Phoenix, Arizona
One Community Health ( Site 0045)
Sacramento, California
Whitman-Walker Institute ( Site 0039)
Washington D.C., District of Columbia
Georgetown University Medical Center-Clinical Trials Unit Division of Infectious Diseases ( Site 002
Washington D.C., District of Columbia
Midway Immunology and Research Center ( Site 0033)
Ft. Pierce, Florida
Orlando Immunology Center ( Site 0017)
Orlando, Florida
Bliss Healthcare Services-Research ( Site 0030)
Orlando, Florida
Triple O Research Institute, P.A ( Site 0031)
West Palm Beach, Florida
Chatham County Health Department - Chatham CARE Center-Infectious Disease ( Site 0015)
Savannah, Georgia
Northstar Healthcare ( Site 0003)
Chicago, Illinois
KC CARE Health Center-Clinical Trials ( Site 0012)
Kansas City, Missouri
ID Care ( Site 0028)
Hillsborough, New Jersey
Icahn School of Medicine at Mount Sinai-Clinical and Translational Research Center ( Site 0006)
New York, New York
Penn Medicine: University of Pennsylvania Health System-Perelman Center for Advanced Medicine ( Site
Philadelphia, Pennsylvania
St Hope Foundation ( Site 0041)
Bellaire, Texas
North Texas Infectious Diseases Consultants, P.A-Research ( Site 0004)
Dallas, Texas
Texas Center for Infectious Disease Associates-Clinical Research ( Site 0026)
Fort Worth, Texas
The Crofoot Research Center ( Site 0008)
Houston, Texas
Holdsworth House Medical Practice ( Site 0700)
Darlinghurst, New South Wales, Australia
St Vincent's Hospital-IBAC ( Site 0702)
Sydney, New South Wales, Australia
Fiona Stanley Hospital ( Site 0706)
Murdock, Western Australia, Australia
Sheldon M. Chumir Health Centre-Southern Alberta Clinic ( Site 0106)
Calgary, Alberta, Canada
Vancouver Infectious Diseases Centre ( Site 0100)
Vancouver, British Columbia, Canada
Hamilton Health Sciences- Urgent Care Centre-SIS Clinic ( Site 0109)
Hamilton, Ontario, Canada
Maple Leaf Research ( Site 0105)
Toronto, Ontario, Canada
Toronto General Hospital ( Site 0104)
Toronto, Ontario, Canada
Clinique de médecine Urbaine du Quartier Latin ( Site 0110)
Montreal, Quebec, Canada
Clinique Medicale lActuel ( Site 0108)
Montreal, Quebec, Canada
Hospital hernan henriquez aravena de temuco-Unidad de Investigación Clínica ( Site 0202)
Temuco, Araucania, Chile
Biomedica Research Group-Infectology ( Site 0201)
Santiago, Region M. de Santiago, Chile
Centro de Investigacion Clinicadela Universidad Catolica ( Site 0204)
Santiago, Region M. de Santiago, Chile
Universidad de Chile - Hospital Clínico Universidad de Chile ( Site 0200)
Santiago, Region M. de Santiago, Chile
Fundacion Valle del Lili- CIC ( Site 0300)
Cali, Valle del Cauca Department, Colombia
Hôpital Bichat - Claude-Bernard-infectious diseases ( Site 1523)
Paris, France
Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 1504)
Nice, Alpes-Maritimes, France
Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1516)
Dijon, Bourgogne-Franche-Comté, France
CHU de Bordeaux Hop St ANDRE-Médecine interne et maladies infectieuses ( Site 1512)
Bordeaux, Gironde, France
CHU de Toulouse-Infectious Disease-Tropical Diseases ( Site 1505)
Toulouse, Haute-Garonne, France
CHU Charles Nicolle-Inefectious disease ( Site 1506)
Rouen, Haute-Normandie, France
Hospital La Colombière ( Site 1518)
Montpellier, Herault, France
Showing 40 of 93 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.